Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Breast Cancer / Mammacarcinoma (BRCA m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

The oral PARP inhibitors are a promising strategy in breast cancer exploiting Homologous Deficient Recombination deficiency (HRD) by a synthetic lethal approach. Several PARP inhibitors have currently reached early phase trials with studies on going in the adjuvant, neoadjuvant and metastatic setting.
Robert et al. 2018a Expert Opin. Emerging Drugs 23: 211-221

References (Sources)

Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib
McCann 2019 Future Oncology 15: 1707–1715
Emerging PARP inhibitors for treating breast cancer
Robert et al. 2018a Expert Opin. Emerging Drugs 23: 211-221
Review
PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
Yan et al. 2021a
Meta-Analysis

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Breast Cancer / Mammacarcinoma (BRCA m)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat